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Cancer stem cells (CSCs) or tumor-initiating cells (TICs) are thought to be the main drivers
for disease progression and treatment resistance across various cancer types. Identifying and
targeting these rare cancer cells, however, remains challenging with respect to therapeutic
benefit. Here, we report the enrichment of LGR5 expressing cells, a well-recognized stem cell
marker, in mouse liver tumors, and the upregulation of LGR5 expression in human hepato-
cellular carcinoma. Isolated LGR5 expressing cells from mouse liver tumors are superior in
initiating organoids and forming tumors upon engraftment, featuring candidate TICs. These
cells are resistant to conventional treatment including sorafenib and 5-FU. Importantly, LGR5
lineage ablation significantly inhibits organoid initiation and tumor growth. The combination
of LGR5 ablation with 5-FU, but not sorafenib, further augments the therapeutic efficacy
in vivo. Thus, we have identified the LGR5+ compartment as an important TIC population,
representing a viable therapeutic target for combating liver cancer.
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The key concept underlying the cancer stem cell (CSC) ortumor-initiating cell (TIC) theory is that tumors aremaintained through a hierarchical structure, in which
different cell populations have different functionalities in patho-
physiology1. The bulk of a tumor is thought to consist of CSCs/
TICs as well as rapidly proliferating cells. CSCs/TICs are
responsible for tumor initiation, resistance to conventional
treatment, and distant metastasis. Rapidly proliferating cancer
cells, thought to be derived from the tumor stem cell pool, are
responsible for volume increment of the tumor2. A prediction
based on this model is that ablation of the relatively small CSC
compartment would ultimately result in cessation of tumor
growth and metastasis, and provoke sensitization of the tumor to
conventional treatment as well.
Within the framework of this theory, CSCs/TICs would be
characterized by a large capacity for self-renewal, a potential for
differentiation into different cell types that constitute the
tumor, and a resistance to conventional treatment1. These key
features largely overlap with those of normal stem cells, making
it extremely difficult to specifically identify CSCs/TICs, but on
the other hand would allow techniques traditionally used for
identifying normal stem cells also to be applied for CSCs/TICs3.
LGR5 (leucine-rich repeat-containing G protein-coupled
receptor 5) evokes special interest as a potential marker for
the CSC/TIC compartment in this respect. LGR5 is a well-
characterized stem cell marker in several tissues/organs,
including the small intestine, colon, and liver4–6. In the colon
and intestine, the LGR5 stem cell pool constantly proliferates
and differentiates into mature cell types to compensate for the
loss of functional epithelial cells. Interestingly, these LGR5 stem
cells also participate in the process of oncogenesis, acting as the
cells-of-origin of intestinal cancer7. Importantly, LGR5 marks
CSCs in colon cancer8–10, intestinal cancer11, and basal cell
carcinoma12. In intestinal adenoma as well as malignant car-
cinoma, LGR5 cells account consistently for a ratio of 5–10% of
tumor cells and fuel tumor growth8,13. Proof-of-concept
showing that specific elimination of LGR5 cells delays tumor
growth in colon cancer has been provided9. Given the essential
role of CSCs/TICs, these cells are attractive targets for antic-
ancer treatment, whereas their resistance to conventional
therapies impedes the therapeutic development.
In contrast to the colon and intestine, LGR5 stem cells are
absent in the homeostatic liver, but emerge upon tissue
injury4,14. These liver LGR5 cells are likely to be an inter-
mediate stem/progenitor cell population that responds to
injury, but they may have a limited contribution to tissue
repair14. Whether an LGR5+ compartment exists in liver cancer
remains obscure, and the possible importance of such a com-
partment in this disease is unexplored. Nevertheless, research
into this possibility is urgently needed as liver cancer is one of
the most common forms of malignancy worldwide, with nearly
800,000 cases reported yearly, and it is characterized by a
depressing lack of treatment options15. Hepatocellular carci-
noma (HCC) and cholangiocarcinoma (CC) are the two main
types of primary liver cancer. Currently, surgery remains the
only potentially curative therapeutic strategy available, but is
well-known for its high recurrence rate following tumor
resection. Chemotherapy and targeted treatment are generally
ineffective, with sorafenib providing some extension of life
expectancy to HCC patients. The unusual treatment resistance
of liver cancer is thought to be associated with the presence of
CSCs/TICs, but this notion remains largely unproven16. Thus,
we aimed to investigate whether LGR5 marks CSCs/TICs in
liver cancer, and to explore the potential for therapeutic tar-
geting of these cells. Our results show that in liver cancer, an
LGR5+ compartment exists that is superior in tumor initiation
and mediates therapy resistance. Targeting this compartment
constitutes a rational avenue for combating this disease.
Results
Enrichment of LGR5-expressing cells in primary liver tumors.
Homeostatic livers are reported to be devoid of LGR5+ cells, but
injury does induce such cells14. Whether LGR5+ cells are present
in liver cancer is largely unknown. By adopting Lgr5–DTR–GFP
knock-in mice (Fig. 1a), we first investigated the presence of
LGR5+ cells (GFP-co-expressing cells) in the healthy and injured
liver, and during carcinogenesis. Carbon tetrachloride (CCl4) was
used to trigger liver injury. Diethylnitrosamine (DEN) was used
to induce primary liver tumor formation (Fig. 1b; Supplementary
Fig. 1). Although LGR5 cells are absent in the homeostatic liver
(Fig. 1c), either a single course or repeated administration of DEN
can rapidly trigger the emergence of LGR5–GFP+ cells (post
DEN induction day 7; relative size of the LGR5–GFP+ com-
partment following 1 × DEN: 0.025 ± 0.05%, n= 3 [mean ±
SEM]; Supplementary Fig. 2a, b). Animals were monitored for
liver tumor formation from 4 to 14 months post DEN induction
(Supplementary Data 1). Analysis of the resulting hepatic neo-
plasms revealed the stable presence of an LGR5+ compartment in
these liver tumors (Fig. 1c). The relative abundance of LGR5 cells
in the tumors (Supplementary Data 1, Supplementary Fig. 2c, d)
is significantly higher as compared with those in the tumor-
surrounding tissues (Fig. 1d) or as detected in CCl4-injured livers
(Fig. 1c). The LGR5 expression levels in the tumor cells show
substantial variation, but are substantially and significantly higher
compared with that in injured liver (Fig. 1e). Immunohis-
tochemistry (IHC) and immunofluorescence (IF) staining of GFP
expression further confirms the presence of an LGR5+ com-
partment and enables detailed analysis of spatial distribution of
LGR5–GFP+ cells in the liver (IF: Fig. 1f; IHC: Supplementary
Fig. 2e, f). Co-staining with hepatocyte marker (HNF4α) or
cholangiocyte marker (CK19) revealed that a proportion of LGR5
cells in the tumor express HNF4α or CK19 (Fig. 1g, h), suggesting
that LGR5+ cells may give rise to both a HCC-like and a CC-like
phenotype, the two main types of primary liver cancer. Thus,
these data have demonstrated the presence of an LGR5+ com-
partment in primary murine liver cancer.
To examine the clinical relevance, we investigated LGR5
expression in human HCC tumors from our patient cohort
(Erasmus MC cohort). We found that LGR5 expression is
significantly elevated in tumor tissues compared with the paired
tumor-free liver tissues (Fig. 2a), and also in some subpopulations
of patients with specific etiologies of HCC (Fig. 2b). Survival
analysis by predicting Kaplan–Meier curves revealed a tendency
toward worse clinical outcome in patients with higher LGR5
expression (Fig. 2c). Further analysis of online publically available
datasets confirmed the upregulation of LGR5 expression in HCC
(Supplementary Fig. 3a), and possible association with clinical
outcome, especially in subpopulations of specific patients
(Supplementary Fig. 3b). Interestingly, with data from the TCGA
database and International Cancer Genome Consortium-France
(LICA-FR) and International Cancer Genome Consortium-Japan
(LIRI-JP), we found that the upregulation of LGR5 expression is
more pronounced in HCC tumors with β-catenin mutation
(Supplementary Fig. 4). This is in line with LGR5 being a β-
catenin target gene both in the intestine and liver5,17. Taken
together, LGR5 cells are enriched in both mouse and human liver
tumors, and bear substantial clinical relevance.
Preservation of LGR5 cells in organoid and allograft tumors.
3D organoid cultures are robust model systems for studying the
properties of (cancer) stem cells18–20. We have successfully
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established routine procedures21 for creating organoid cultures
from primary liver tumors of DEN-induced mice (Supplementary
Fig. 1). In total, 89 tissues were obtained from 41 individual
murine livers (Supplementary Data 1). In all, 63 out of 89 (70.8%)
tumor/tumor-surrounding tissues successfully initiated organoids
(8 out of 34 tumor-surrounding tissues did not initiate organoids,
23.5%; 18 out of 55 tumor tissues did not initiate organoids,
32.7%). These organoids can be maintained and propagated in
3D culture for at least 5 months. Staining for CK19 and
HNF4α demonstrates that these organoids display either a CC or
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HCC-like phenotype (Fig. 3a, b). Importantly, these cultured
organoids maintain a population of LGR5-positive cells (Fig. 3c).
To investigate whether these murine organoid lines are
malignant, we transplanted all the 63 strains into immunodefi-
cient NOG mice (Fig. 3d). One to 6 months after allografting, 11
out of 63 organoid strains formed palpable tumors in the
immune-deficient mice (17.5%). All contained an LGR5–GFP+
compartment as determined by FACS analysis of the tumors
(Fig. 3e).
Following re-culture of cells obtained from these allograft
tumors as organoids, we observed substantial diversity of the
morphology (Supplementary Fig. 5a–c) and CK19/HNF4α
expression in the corresponding allograft tumors (Fig. 3f;
Supplementary Data 2). A population of LGR5-expressing cells
were again observed in these organoid cultures (Supplementary
Fig. 5d), in line with the existence of such a compartment in the
allograft tumors from which these organoid cultures originated
(IF: Supplementary Fig. 5e; IHC: Supplementary Fig. 5f and
Fig. 1 Primary murine liver tumors are enriched with LGR5-expressing cells. a Principle of Lgr5–DTR–GFP transgenic mouse strategy used in this study.
b Principle of the experimental strategy used to induce primary murine tumors in the context of this study. c The percentage of LGR5+ cells, as determined
by flow cytometry, is significantly higher in liver tumors from DEN-treated (7.29 ± 1.76%, n= 55) as compared with livers from untreated animals (0 ± 0%,
n= 8) or injured livers from CCl4-treated animals (0.11 ± 0.022%, n= 17) (Welch test, P= 0.0001). d The percentage of LGR5–GFP+ cells is significantly
increased in liver tumors (7.29 ± 1.76%, n= 55) as compared with the tumor-surrounding tissues (2.93 ± 1.15%, n= 34) of the same mice (Welch test, P=
0.0407). e Liver tumor-derived LGR5–GFP+ cells showed increased fluorescence intensity when compared with LGR5–GFP+ cells derived from CCl4-
injured livers. f Representative images showing LGR5–GFP+ cells as present in liver tumors. Yellow arrow: LGR5–GFP+ cell. DAPI: blue. Upper panels: scale
bar= 50 µm; lower panels: scale bar= 20 µm. g, h Representative confocal images showing the expression of the cholangiocyte marker (g, CK19, yellow)
and the hepatocyte-specific marker (h, HNF4α, red) in LGR5–GFP-expressing cells, Scale bar= 50 µm. Mean ± SEM. Source data are provided as a Source
Data file.
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Fig. 2 The expression of LGR5 is upregulated in human HCC tissues. a Upregulation of LGR5 expression in HCC tissues (n= 74) compared with tumor-
free liver tissues (TFL, n= 75) from the Erasmus MC cohort (paired T test, P= 0.0066). GUSB (beta-glucuronidases), HPRT1 (hypoxanthine
phosphoribosyltransferase 1), and PMM1 (phosphomannomutase 1) were used as reference genes for normalization. b The expression of LGR5 in HCC
tissues compared with TFL stratified based on the etiologies of HCC (paired T test). FHCC fibrolamellar carcinoma, HBV hepatitis B virus, HCV hepatitis C
virus, NASH nonalcoholic steatohepatitis, Alc alcohol. Patient number: alcohol (n= 16); FHCC (n= 3); HBV (n= 9); HCV (n= 5); HCV+ alcohol (n= 6);
NASH (n= 8); unknown (n= 21); HBV+Alc/NASH/HCV (n= 5). c Kaplan–Meier curve of HCC patient survival with high (n= 37) and low (n= 37) LGR5
expression (cutoff value based on median value—0.047). Mean ± SEM. Source data are provided as a Source Data file.
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Supplementary Data 2). In addition, genome-wide transcrip-
tomic analysis revealed a distinct gene expression signature
between LGR5+ and LGR5− cells, including TATA-box
binding protein-associated factor 7 like (Taf7l), sialophorin
(Spn), SRY-box 2 (Sox2), nidogen-1 (Nid1), paralemmin 3
(Palm3), alpha-1-microglobulin/bikunin precursor (Ambp),
membrane-bound O-acyltransferase domain containing 4
(Mboat4), and chymase 1 (Cma1), which had higher expression
levels in LGR5+ compared with LGR5− population.
Kaplan–Meier curve analysis revealed that all these genes are
associated with the survival of liver cancer patients (Supple-
mentary Fig. 6, Supplementary Data 3–4). Especially, Sox2 as a
transcription factor is essential for maintaining self-renewal or
pluripotency of undifferentiated embryonic stem cells, and has
been reported as a marker for cancer stem cells in breast cancer
and squamous-cell carcinoma22. Gene enrichment analysis of
the 196 differentially expressed genes further revealed the
involvement of metabolism-related pathways, including “Oxi-
dation by Cytochrome P450”, “Calcium Regulation”, “Meta-
pathway biotransformation”, and “Purine metabolism”. There
are also differentially expressed genes involved in immune
regulation, including “Macrophage markers pathway”, “Kit
Receptor Signaling Pathway”, and “IL-6 signaling Pathway”.
Furthermore, LGR5+ cells had significantly differentially
expressed genes involved in cell proliferation/migration,
including “Chemokine signaling pathway”, “Matrix Metallo-
proteinases”, and “PPAR signaling pathway”. Interestingly,
there are differentially expressed genes enriched in “Wnt
Signaling Pathway” and “G Protein Signaling Pathways”.
Subsequent experiments were initiated to assess the exact
functionality of LGR5- expressing cells.
LGR5+ cells are superior in organoid and tumor initiation. For
functional comparison of LGR5+ and LGR5− liver cancer cells,
we first assessed their relative clonogenic ability using an orga-
noid initiation assay. Employing FACS (the sorting strategy:
Supplementary Fig. 7a), LGR5–GFP+ and LGR5–GFP− cells were
collected from 71 individual primary murine liver tissues, and
cultured in 3D matrigel (Fig. 4a; Supplementary Data 5). After
2–3 weeks, we observed organoid formation from single cells
(Fig. 4b–d). Importantly, LGR5–GFP+ cells have stronger orga-
noid formation ability compared with LGR5–GFP− cells (2.13 ±
0.67% vs. 0.07 ± 0.02%, n= 30) (Supplementary Data 5: detailed
organoid initiation efficiency). In addition, we also observed that
the initiation ability of LGR5+ cells showed close correlation to
collected cell number. The average numbers of LGR5+ cells
collected from tissues that did initiate organoid (1906 ± 442, n=
25) were significantly higher compared with the number that did
not (171 ± 47, n= 46). This was not the case for LGR5− cells
(28350 ± 8914, n= 60 vs. 13860 ± 3654, n= 11) (Supplementary
Fig. 7b–d). This indicates that a sufficient cell number (>1000) is
essential for successful organoid initiation of LGR5-expressing
cells from liver tumors.
We next performed organoid initiation for cells derived from
the allograft tumors (Fig. 4e). Similar as observed with primary
tumors, LGR5+ cells of allograft tumors initiate more organoids
as compared with LGR5− cells (40.5 ± 10.2% vs. 9.8 ± 3.9%, n=
10) (Fig. 4f). Compared with cells isolated from primary tissues,
allograft tumor cells are more potent with respect to their
potential for organoid initiation (Supplementary Fig. 7e–g).
Interestingly, organoids formed from a single LGR5–GFP+ or
LGR5–GFP− cell produce both LGR5-positive and -negative
offspring, suggesting possible self-formation of a hierarchical
organization sustaining organoid growth and differentiation
(Supplementary Fig. 7h).
The ultimate measure of potential functionality of LGR5+ cells
in pathophysiology is their capacity to form allograft tumors
in vivo (Fig. 4g). Hence, identical numbers of FACS-sorted
LGR5–GFP+ and LGR5–GFP− cells derived from primary liver
tumors were subcutaneously engrafted into NOG mice, and
tumor formation was monitored (Supplementary Data 6). As
expected, LGR5+ cells display a stronger capacity for tumor
initiation as compared with LGR5− cells (LGR5+ vs. LGR5−:
33.3% vs. 11.1%) (Fig. 4h; Supplementary Data 6). Moreover,
tumors initiated from LGR5+ cells contain both LGR5-positive
and -negative populations (Fig. 4i–n). In addition, we have
performed a tumor formation assay for the cells that were derived
from the allograft tumors (Fig. 4o). Again, the LGR5+
compartment proved markedly more potent in this respect
relative to the LGR5–GFP− compartment (Fig. 4p, q; Supple-
mentary Table 1). Collectively, our results are best interpreted
that liver tumor-derived LGR5+ cells constitute a bona fide TIC
compartment.
Anticancer treatment enriches LGR5-expressing cells. CSCs or
TICs are presumed to be relatively resistant to conventional
anticancer treatment. A prediction would thus be that in liver
cancer, the LGR5+ cells would be more resistant to anticancer
treatment as compared with the LGR5− cells. Hence, we chal-
lenged tumor organoids with sorafenib, the FDA-approved drug
for treating advanced HCC, and compared the relative potential
of LGR5–GFP+ and LGR5–GFP− cells to withstand such treat-
ment (Fig. 5a). Treatment of tumor organoids with sorafenib
significantly increased the percentage of LGR5-positive cells in
the population (Fig. 5b–d). This effect became even more pro-
found when the organoids were treated with the chemother-
apeutic agent, 5-fluorouracil (5-FU) (Fig. 5a–d).
Subsequently, the relative size of the LGR5+ compartment
following in vivo treatment with these therapeutic agents was
assessed (Fig. 5e). Treatment with either sorafenib or 5-FU to
mice-bearing allograft tumors, formed by engrafting tumor
organoids, substantially increased the fraction of the
LGR5–GFP+ cells in the tumors (Fig. 5f). Also when
LGR5–GFP+ and LGR5–GFP− cells were isolated from tumor
organoids and used for organoid re-initiation, while subsequently
being treated with 5-FU, the resulting cultures were dominated by
LGR5–GFP+-expressing cells, independent from whether
LGR5–GFP+ or LGR5–GFP− were used as starting material
(Fig. 5g). Of note, LGR5+ cells isolated from 5-FU-treated tumors
retained the ability of organoid and tumor initiation (Supple-
mentary Fig. 8). Interestingly, 5-FU treatment effectively rewired
the transcriptome of LGR5+ cells (Fig. 5h; Supplementary Figs. 6
and 9). Gene enrichment analysis of the 1464 differentially
expressed genes between 5-FU treated compared with untreated
LGR5+ cells revealed the involvement of stem cell-related
pathways, including “Wnt Signaling”, “Notch Signaling Pathway”,
“ErbB signaling pathway”, “Hedgehog Signaling Pathway”, and
“BMP Signaling Pathway” (Fig. 5i; Supplementary Data 3). These
pathways are commonly activated in many types of solid tumors,
associated with cancer initiation, progression, and metastasis23.
Interestingly, there are several pathways, including “TGF Beta
Signaling Pathway”, “EGFR1 Signaling Pathway”, “PPAR signal-
ing pathway”, “G1 to S cell cycle control”, “Mismatch repair”,
“p53 signaling”, and “Apoptosis Modulation/Apoptosis pathway”,
which are known to be implicated in anticancer treatment
response and DNA damage response24. These results may
partially explain the enrichment of LGR5-expressing cells upon
5-FU treatment. In conclusion, besides resistance, conventional
anticancer treatment also triggers the generation and propagation
of LGR5-expressing cells.
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LGR5 lineage ablation inhibits organoid and tumor growth.
From the results described above, we inferred that ablation of
the LGR5+ compartment should impair liver cancer growth. To
experimentally test this notion, we exploited the co-expression
of the diphtheria toxin receptor (DTR) in the Lgr5–DTR–GFP
mice. This would allow us to specifically deplete the
Lgr5–DTR–GFP+ compartment through diphtheria toxin (DT)
administration (Fig. 1a). We have optimized the concentrations
of DT treatment (1–10 ng/ml) for LGR5 depletion, with orga-
noids derived from healthy Lgr5–DTR–GFP mice14. Accord-
ingly, we evaluated the effects on organoid initiation and
proliferation (Fig. 6a, b), and sorafenib treatment served as a
positive control. DT treatment inhibited the growth of tumor
organoids in an effect that showed close correlation as to the
effects on the numbers of LGR5–GFP+ cells (Fig. 6c–e). DT
treatment did not influence the growth of tumor organoids of
genetically wild-type (Fig. 6c: left panel).
We further assessed therapeutic targeting of LGR5 liver
cancer cells in vivo. We first evaluated the effect of DT
treatment after formation of visible tumors, following trans-
plantation of tumor organoids into immunodeficient mice
(Supplementary Fig. 10a). 5-FU and sorafenib served as the
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positive controls. The effects of LGR5 cell depletion on the
growth of formed tumors was minor (Supplementary Fig. 10c:
right panel and 10d: right panel). In contrast, administration of
DT immediately after transplantation of tumor organoids
(Fig. 6f) efficiently delayed tumor initiation and inhibited their
growth (Fig. 6h; Supplementary Fig. 10c: left panel and 10d: left
panel). Further analysis of the tumors confirmed the depletion
of the LGR5–GFP+ compartment in the DT-treated animals
(Fig. 6g). Using absolute tumor size as a measure, DT-mediated
depletion of the LGR5+ compartment impaired tumor growth
(Fig. 6i). The enrichment of stem cell markers also differed in
control and DT-treated LGR5+/− cells (Supplementary Fig. 11).
Interestingly, there was an inverse correlation between tumor
and the relative size of the LGR5–GFP+ compartment at the
end of the experiment (Supplementary Fig. 10e, f), indicating
that LGR5-expressing cells are probably more active in the
tumor initiation period. As control, DT treatment did not
influence initiation and growth of tumors formed from the
wild-type tumor organoids (Supplementary Fig. 12a, b). Thus,
LGR5 lineage ablation impedes organoid and tumor initiation
and further growth.
Combination therapy enhances the anticancer efficacy. As
LGR5+ cells appear to mediate resistance against conventional
anticancer treatment, it is rational to evaluate the combination of
LGR5+ lineage ablation with conventional anticancer treatment.
To experimentally test this notion, we first combined DT with
sorafenib treatment. However, with different strategies of
combination therapy, no enhanced antitumor activity was
observed on allografted tumors (Fig. 7). We next tested the
combination of 5-FU and DT. Allograft tumor-bearing mice were
first subjected to 5-FU (which increases the relative size of the
LGR5+ compartment) followed by cessation of 5-FU therapy and
start of DT treatment as to kill the LGR5+ cells (Fig. 8a;
Supplementary Fig. 13a–c). Indeed, this approach is effective in
combating allograft tumor formation (Fig. 8b) and is substantially
superior to monotherapy with 5-FU, stand-alone DT treatment
(Fig. 8c, d; Supplementary Fig. 14a) or initial treatment with DT
followed by 5-FU therapy (Supplementary Fig. 13d–h). Simulta-
neous administration of 5-FU and DT (Fig. 8e) also resulted in
anticancer effects (Fig. 8f–h; Supplementary Fig. 14b). Thus,
targeting the LGR5+ compartment markedly enhances the
efficacy of conventional treatment aimed at combating liver
cancer.
Discussion
This study has demonstrated that liver cancer contains an LGR5+
compartment that has various hallmarks of TICs/CSCs, including
an increased capacity for tumor organoid formation in culture
and allograft formation in mice, as well as resistance against
conventional anticancer therapy. Functionally, these cells seem
more important in tumor initiation, whereas the LGR5− com-
partment appears to bear the proliferative burden. Simultaneously
targeting both compartments as demonstrated in this study by 5-
FU treatment in combination with DT-mediated ablation of the
LGR5+ compartment was effective in combating liver cancer in
experimental models. Although our study primarily focused on
mouse models, the relevance of the LGR5+ compartment
deserves to be further investigated in human liver cancer. Con-
ceivably, the role of these cells could be more prominent for a
subset of patients with high levels of LGR5 expression, such as
CTNNB1-mutated or alcohol-related HCC patients25,26.
Although LGR5+-targeting therapies are still largely in their
infancy, the analogy with neuroendocrine tumors, which are
successfully combated by radioactive somatostatin analogs (e.g.,
177Lu-Dotatate) that target receptors with homology to LGR527,
suggests that radioactive drugs (e.g., R-spondin) may be explored
for developing CSC-targeted therapeutics against liver cancer28.
Our results, however, indicate that such therapy may require
combination with particular conventional anticancer therapies to
enhance the efficacy.
Overexpression of LGR5 has been previously reported in
patient HCC17, and we confirmed that this is more pronounced
in β-catenin-mutated liver tumors. Although the elevation of
LGR5 expression and potential association with clinical outcome
have been observed in HCC patients, whether it can serve as an
independent prognostic biomarker remains to be further inves-
tigated in specifically designed tumor marker prognostic studies
in patients29.
Of note, these early observations are based on mRNA
expression, due to the lack of a reliable anti-LGR5 antibody. We
now used transgenic mice in which LGR5-expressing cells co-
express GFP, and we can conditionally ablate these cells with the
DT-DTR system30. This model allows for the identification and
direct visualization of LGR5-expressing cells based on GFP
expression, as well as isolation of LGR5–GFP+ cells for further
functional analyses and detailed characterization.
In intestinal adenomas, LGR5 marks 5–10% of the cells,
which keep fueling the growth of established mouse adeno-
mas13. We found that the percentages of LGR5–GFP+ cells in
murine liver tumors vary from 0.1% up to 55% (7.3 ± 1.8%, n=
55). Over 32% of the primary liver tumors harbor relatively
high percentages (over 5%) (Supplementary Fig. 2c). In colon
cancer, the percentage of LGR5-expressing cells has been
reported to be associated with different background of the
tumors, especially the accumulation of certain oncogenic
mutations8. Thus, we speculate that the large variation of the
Fig. 4 Single LGR5+ cells from liver tumors are superior in organoid and tumor initiation. a An outline of the experimental strategy for studying ex vivo
organoid initiation of cells derived from primary murine liver tumors. b A representative picture of organoids derived from single LGR5+ cells. Scale bar=
50 µm. c Representative confocal micrograph of a single LGR5+ cell-initiated organoid dominated by LGR5-expressing cells. LGR5-driven GFP: green. Scale
bar = 20 µm. d Organoid initiation efficiency of LGR5–GFP+ and LGR5–GFP− cells, isolated from primary tumors (LGR5+ cells: 25 out of 71 tissues, 35.2%;
LGR5− cells: 11 out of 71 tissues, 15.5%) (paired T test, 2.13 ± 0.67% vs. 0.065 ± 0.023%, n= 30, P= 0.0048). e An outline of the strategy used to study
ex vivo organoid initiation of allograft tumor-derived cells. f Efficiency of organoid initiation by allograft liver tumor-derived LGR5–GFP+ and LGR5–GFP−
cells (paired T test, 40.46 ± 10.19% vs. 9.84 ± 3.93%, n= 10, P= 0.0187). g Outline of the experimental strategy used to assess in vivo tumor initiation of
cells isolated from primary murine liver tumors. h Weight of tumors initiated by LGR5+ and LGR5− cells (LGR5+ vs. LGR5−: 0.46 ± 0.046 g vs. 0.10 ±
0.10 g, n= 3) (formed tumor number: LGR5+ cells—3 out of 9; LGR5− cells—1 out of 9). i LGR5 expression in single LGR5+ cell-derived allograft tumors and
the corresponding primary tumors (17.42 ± 15.29% vs. 2.47 ± 1.27%, n= 3). j–n Representative pictures showing that LGR5–GFP+ and LGR5–GFP− cells
(k) were isolated from DEN-induced primary liver tumors (j). Then, LGR5–GFP+ cells (green arrow) initiated allograft tumors in immunodeficient mouse
(l–n). The initiated allograft tumors sustained LGR5 expression (n). o An outline of the experimental strategy for in vivo tumor initiation assay of cells
isolated from allograft murine liver tumors. p, q Tumor weight (p) and macroscopic aspect (q) of allografts initiated by LGR5–GFP+ cells and LGR5–GFP−
cells (isolated from allograft tumors) (0.64 ± 0.19 g vs. 0.27 ± 0.08 g, n= 11, P= 0.0418). Mean ± SEM. Source data are provided as a Source Data file.
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abundance of LGR5 cells in murine liver tumors may also be
related to different types of oncogenic mutations, although this
hypothesis requires further investigation. Of note, DEN was
used to induce primary liver cancer in this study, and this
compound is associated with the accumulation of liver β-
catenin mutations31. Therefore, it is possible that our results are
mainly relevant to liver cancers with deregulated Wnt/β-catenin
signaling, and their importance requires further investigation in
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other mutational backgrounds (e.g., deregulated TSC/mTOR
signaling)32 as well.
Through a series of functional assays, in particular in vitro
organoid initiation and in vivo tumor formation, we have
demonstrated the importance of these LGR5 TICs in liver
cancer. To define the potential for therapeutic targeting, we
have performed LGR5 lineage ablation in organoids in vitro and
in the tumor-bearing mouse model. Of note, the presence of
LGR5 cells in tumors is likely dynamic. We observed large
variations of their percentages among different primary murine
liver tumors, and allograft tumors generally contain lower
numbers of LGR5 cells (less than 1%). In colorectal cancer,
advanced stages compared with the early stages contain less
LGR5 cells33. A speculative explanation could be that the
tumors are derived from LGR5-positive stem cells, yet these
cells are suppressed thereafter during tumor progression33. The
dynamics could be essential for determining at which stage to
target LGR5 TICs. When we performed LGR5 cell ablation in
established tumors, we only observed a minor effect, probably
due to a low percentage of LGR5 cells as well as their dis-
pensable function at that stage, while depletion at the early
stage yielded optimal antitumor effects. This result is in line
with previous findings showing that LGR5 cells play distinct
roles in primary and metastatic colon cancer8. In addition, the
percentage of LGR5-expressing cells in primary murine tumors
seems not strictly correlated with the ability of initiating allo-
graft (Fig. 3e). Because primary tumors were first cultured into
tumor organoids, these organoids were engrafted into mice to
initiate the allograft. Thus, this indirect assay may not fully
recapitulate the initial status of the primary tumor.
Although we have demonstrated the feasibility and value of
targeting LGR5 TICs in murine liver cancer, therapeutic ablation
of these cells remains challenging. Resistance to conventional
therapy is a common feature of CSCs2. We found that treatment
with sorafenib or 5-FU enriches LGR5 cells, consistent with the
findings in gastric34 and colorectal cancer35. Different mechan-
isms may contribute to treatment resistance. Although
LGR5 stem cells are generally fast-cycling in the intestine36, the
existence of quiescent LGR5 cells has been reported in basal cell
carcinoma, which mediates relapse after treatment12. Cell plasti-
city could be one of the potential mechanisms of treatment
resistance. The loss of LGR5 stem cells in the intestine can be
compensated by transdifferentiation from other stem cell pools30,
or through plasticity of their enterocyte-lineage daughters37.
Cancer cell plasticity, shifting dynamically between a differ-
entiated and a stemness state, has also been proposed as an
important feature contributing to tumor progression, metastasis,
and therapeutic response38. We have now observed the induction
of LGR5+ from LGR5− liver cancer cells. This may implicate cell
plasticity of LGR5 CSCs, but there could also be other mechan-
isms regulating the origin and expansion of LGR5 cells, as for
example, changes in the culture environment. Eventually, these
LGR5 liver cancer cells may partially contribute to treatment
resistance.
Currently, several innovative scenarios are being explored to
therapeutically target CSCs, including antibody–drug con-
jugates9, targeting quiescent CSCs39, and inhibiting CSC-
related pathways2. However, as discussed, different mechan-
isms could lead to treatment resistance8. Thus, combined
therapies are likely necessary in this respect. With the intention
to fully expand the stem cell pool, cetuximab has been used to
first trigger the LGR5 population, followed by the ablation of
these CSCs. This combined therapy has resulted in potent
efficacy against colorectal cancer10. Similarly, we have observed
that the combination of LGR5 lineage ablation with 5-FU
chemotherapy can also lead to enhanced anti-liver cancer
activity in mouse organoid. However, a combination of LGR5
lineage ablation with sorafenib did not yield enhanced anti-
tumor activity. This is probably related to the mild effect of
sorafenib in triggering the LGR5 CSC pool.
Last, a potential concern of such strategies is the possible
harmful effects on normal LGR5 stem cells. In the intestine,
colon, and skin, although LGR5 stem cells essentially contribute
to tissue renewal at a daily basis5,6, their loss can be compen-
sated by transdifferentiation from other reserve stem cell
pools30,40 or through plasticity of their daughter cells37.
Importantly, antibody-conjugated drug targeting LGR5 CSCs in
colon cancer has no major impact on the function of normal
LGR5 stem cells9. In the liver, LGR5 stem cells are absent
during homeostasis, but only transiently activated upon injury
likely without major contribution toward tissue repair4,14.
Thus, we envision that our identification of targetable LGR5
TICs in murine liver cancer bears important implications for
future therapeutic development.
Methods
Primary liver tumor model. Lgr5–DTR–GFP transgenic mice (kindly provided by
Genentech) specifically co-express the diphtheria toxin (DT) receptor (DTR) and
green florescent protein (GFP) under the control of the Lgr5 promotor30. Thus,
LGR5+ cells can be identified by GFP expression, and LGR5–GFP+ cells can be
specifically depleted by DT administration. Lgr5–DTR–GFP transgenic mice
(3–4 weeks) were administered with diethylnitrosamine (DEN) by intraperitoneal
injection (Sigma-Aldrich, i.p., 100 mg/kg) weekly for 6–17 weeks41. DEN is used to
induce liver tumor in Lgr5–DTR–GFP transgenic and wild-type mice, which could
cause liver disease from basophilic foci, hyperplasic nodules, hepatocellular ade-
noma, and finally lead to HCC31,42,43. Mice were killed 3–16 months after the last
DEN injection, and livers/tumors were collected for further experiments (Supple-
mentary Data 1: in total, 41 mice were monitored; 80.5%, 33 out of 41, mice formed
liver tumors; the expression of LGR5 in each tumor/tumor-surrounding tissues was
also listed; Supplementary Fig. 2g, h). For each liver, biopsies were taken from the
tumor and tumor- surrounding tissue. If livers contain more than one tumor,
individual tumors were collected and analyzed separately. For CCl4-induced liver
injury, Lgr5–DTR–GFP transgenic mice were weekly repeated administered with (6
or 17 weeks) intraperitoneal CCl4 injection (10 µl/20 g body weight of 10% CCl4
solution in corn oil or corn oil as control). All animal experiments were approved
by the Committee on the Ethics of Animal Experiments of the Erasmus Medical
Center.
Fig. 5 Anticancer treatment selects for LGR5+ cells. a Outline of the ex vivo experimental strategy used to assess the effects of drug treatment on the
size of the LGR5+ compartment. b The fraction of LGR5–GFP+ cells is significantly increased upon treatment with sorafenib or 5-FU (vehicle control vs. 10
µM sorafenib vs. 10 µM 5-FU: 2.6 ± 0.5% vs. 4.6 ± 0.4% vs. 21.3 ± 1.9%). c, d Representative FACS plots (c) and confocal pictures (d) demonstrating that
the fraction of LGR5–GFP+ cells is increased upon treatment with sorafenib or 5-FU, scale bar= 50 µm. e An outline of the experimental strategy used for
testing the effects of drug administration in vivo. f The percentages of LGR5–GFP+ cells is increased upon administration of sorafenib or 5-FU to allografted
animals (vehicle control vs. sorafenib vs. 5-FU: 0.13 ± 0.04%, n= 6 vs. 0.42 ± 0.13 %, n= 8 vs. 0.66 ± 0.17%, n= 7). g Representative confocal pictures
showing that both single LGR5–GFP+ and LGR5–GFP− cell-initiated organoids contain LGR5-expressing cells, and the relative fraction of LGR5-expressing
cells is increased in treatment-resistant organoids. LGR5-driven GFP: green, scale bar= 50 µm. h A volcano plot showing the most significantly
differentially expressed genes between 5-FU treated/untreated LGR5+ cells. i Gene enrichment analysis (with the library of Wiki2019) within the
differentially expressed genes. Mean ± SEM. Source data are provided as a Source Data file.
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HCC specimens and patient information. HCC specimens (paired tumor tissue
and adjacent tumor-free liver tissue) were collected from HCC patients undergoing
tumor resection at the Erasmus Medical Center, The Netherlands. Samples were
stored at −80 °C and then used for RNA extraction. In total, 74 specimens were
obtained from HCC patients, and the corresponding clinicopathological data are
summarized in Supplementary Table 2. HCC-specific survival was assessed in all
patients and they were stratified according to relative LGR5 expression (below and
above median – 0.047). The Kaplan–Meier method was used to estimate survival
outcome curves, and the log-rank test was used to compare the survival between
the two groups. The hazard ratio (HR) for HCC-specific survival was estimated
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using the Cox proportional hazard regression model. The study was approved by
the medical ethical committee of Erasmus Medical Center, and all the patients
signed the informed consent before tissue donation. In addition, the study protocol
conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
Online database. For analysis of LGR5 mRNA expression, data were retrieved
from three independent HCC cohorts, including The Cancer Genome Atlas
(TCGA), Wurmbach44, and Roessler45. For survival analysis based on LGR5
mRNA expression, the TCGA cohort was used. For analysis of the relationship
between gene mutation and LGR5 expression, three independent cohorts were
investigated, including TCGA, International Cancer Genome Consortium-France
(LICA-FR), and International Cancer Genome Consortium-Japan (LIRI-JP).
Tumor organoid culture. Digestion solution II (37 °C, 30 min, 500 µg/ml of col-
lagenase type XI, 200 µg/ml of Dnase-1, 1% FBS in DMEM medium) (collagenase
type XI: Sigma-Aldrich; Dnase-1: Sigma-Aldrich) was used to digest liver or tumor
tissues into single-cell suspension. Single-cell suspension was directly mixed with
matrigel (Corning BV) and then used for culturing, or sorted for further experi-
ments. Sorted cells were also mixed with matrigel and seeded for organoid
initiation. Cells were cultured in organoid culture medium, which was based on
advanced DMEM/F12 (Invitrogen), supplemented with 1% (vol/vol) of N2 (Invi-
trogen), 2% (vol/vol) of B27, 1.25 μM N-acetylcysteine (Sigma-Aldrich, antioxidant
agent), 10 nM gastrin (Sigma-Aldrich), 50 ng/ml EGF (Peprotech, epidermal
growth factor), 10% (vol/vol) of R-spondin-1 (conditioned medium produced by
293T-H-RspoI-Fc cell line, WNT/β-catenin signaling pathway activator), 100 ng/
ml FGF10 (Peprotech, fibroblast growth factor 10), 10 mM nicotinamide (Sigma-
Aldrich), and 50 ng/ml HGF (Peprotech, hepatocyte growth factor). For the first
8–12 days, organoids were supplemented with 10 μM Y-27632 (Sigma-Aldrich),
Noggin, and Wnt3a-conditioned medium. The medium was refreshed every 2 days,
and passage was performed in split ratios of 1:2–1:15 weekly. The proposed tumor
organoid phenotypes are based on the expression of EpCAM/CK19 positive for
CC-like and HNF4ɑ/AFP positive for HCC-like phenotype.
Histology, immunohistochemistry, and immunofluorescence. The liver or
tumor was fixed in 4% paraformaldehyde (PFA) overnight at 4 °C. For immuno-
fluorescence, samples were further dehydrated with 30% sucrose (Sigma-Aldrich,
4 °C, overnight), stored at −80 °C, and then sectioned at 8 μm for further analysis.
Images were acquired with a Zeiss LSM510META confocal microscope. For his-
tology and immunohistochemistry, materials were dehydrated with 70% ethanol,
embedded with paraffin, and sectioned at 4 μm for staining. Images were acquired
with a Zeiss Axioskop 20 microscope. All antibodies are listed in Supplementary
Table 3.
Organoid-based allograft tumor model. Cold advanced DMEM/F12 medium was
used to collect the organoids. After centrifuging, the supernatant was discarded and
organoid pellets (organoid fragmentation size: range from 5 to 150 µm) were mixed
directly with matrigel in a ratio of 1:1 with a total volume of 200 µl. In total, 4–6-
week-old female NOD.Cg-PrkdcSCIDIl2rgtm1Wjl/SzJ (NSG) mice, NOG/JicTac
(CIEA NOD.Cg-Prkdc-scid Il2rg-tm1Sug) mice, or nude mice (NMRI:BomTac-
Nude) were purchased from Taconic, and subcutaneously injected with the col-
lected tumor organoids. The characterization of phenotypes for murine allograft
tumor is based on the expression of EpCAM/CK19 for CC-like and HNF4ɑ/AFP
for HCC-like phenotype (Supplementary Data 2). Tumor dimensions were mea-
sured using calipers, and tumor volume was calculated as 0.523 × length × width ×
width9. Tumor formation was monitored every other day, and mice were killed to
harvest tumors after the tumor diameter reached ~2 cm. Tumor tissues were stored
or cultured as described above.
Cell ablation by DT and treatment of 5-FU/sorafenib. To ablate LGR5+ cells in
organoids, DT (Calbiochem, 1–10 ng/ml) was added to organoid expansion/
initiation medium, followed by further analysis14. For in vivo ablation, DT was
administered via intraperitoneal injection every other day (50 µg per kg body
weight). If mice suffering from weight loss ≥ 10%, compared with the previous
injection, the injection was omitted. 5-FU/sorafenib were also administered via
intraperitoneal injection every other day (5-FU/sorafenib: 30 mg per kg body
weight) (sorafenib: Bio-Connect BV; 5-FU: Sigma-Aldrich).
qRT-PCR. For freshly FACS-sorted cells and HCC specimens, RNeasy Micro Kit
(QIAGEN) was used to isolate RNA. For organoids, Machery-NucleoSpin RNA II
kit (Bioké) was used. Quantification was measured with Nanodrop ND-1000
(Wilmington). RNA was then converted to cDNA by using a cDNA Synthesis kit
(TAKARA BIO INC.). Real-time PCR reactions were performed with SYBRGreen-
based real-time PCR (Applied Biosystems®) and amplified in a thermal cycler
(GeneAmp PCR System 9700). For cells collected from murine tissues, glycer-
aldehyde 3-phosphate dehydrogenase (Gapdh) gene was used as reference. For
quantification of LGR5 mRNA in human tumors and tumor-free liver tissues, Gusb
(beta-glucuronidases), Hprt1 (hypoxanthine phosphoribosyltransferase 1), and
Pmm1 (phosphomannomutase 1) were used as reference genes. All primers are
listed in Supplementary Table 4.
RNA sequencing. The total RNA was isolated using RNeasy Micro Kit (QIAGEN).
The quantity of RNA was measured by a NanoDrop 2000. The collected RNA was
further amplified by using SMARTer kit. Then, RNA sequencing was performed by
Novogene with the paired-end 150-bp (PE 150) sequencing strategy. Gene
expression was analyzed. The identification of differentially expressed genes is
based on P < 0.05 and absolute values of logFc > 1.5. GSEA with the library of
Wiki2019 was performed to reveal the alteration of signaling pathways.
FACS analysis. For FACS analysis, single cells derived from liver tumors/tumor-
surrounding tissues or organoids were suspended in DMEM plus 2% FBS. Cell
suspensions were analyzed using a BD FACSCalibur or BD FACSAriaTM II. For
FACS sorting, a BD FACSAriaTM II cell sorter was used to isolate the target cell
population. Propidium iodide (PI) staining was performed to exclude dead cells,
and CD45 staining was adopted for excluding leucocytes.
Metabolic activity analysis of organoids. Different organoid lines were seeded
separately in a 24-/48-well plate. Sorafenib (10 µM) or 5-FU (10 µM) was added to
the organoid culture since the initial day or post initiation day 3, respectively.
Drugs were refreshed every other day. At days 6–7, organoids were incubated with
Alamar Blue (Invitrogen, 1:20 in DMEM) for 4 h (37 °C), and then the medium
was collected for analysis of the metabolic activity of the cells. Absorbance was
determined by using fluorescence plate reader (CytoFluor® Series 4000, Perseptive
Biosystems) at the excitation of 530/25 nm and emission of 590/35. Each treatment
condition was repeated four times and matrigel with medium only was used as a
blank control.
Statistical analysis. Prism software (GraphPad Software) was used for all statis-
tical analyses. For statistical significance of the differences between the means of
groups, we used Mann–Whitney U test; for statistical significance of the differences
between groups with inequivalent sample sizes, we used Welch test; for statistical
significance of the differences between paired samples, we used paired T test; for
statistical significance of the differences between multiple independent groups, we
used two-way ANOVA (except for Mann–Whitney U test, the use of other sta-
tistical methods is indicated in the legends). Differences were considered significant
at a P value less than 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Fig. 6 LGR5 lineage ablation inhibits organoid and tumor growth. a, b The outlines of the ex vivo experimental strategy to assess the effects of anticancer
drug treatment on organoid initiation, and delineate its temporal aspect (a) or during organoid expansion (b). c The response of wild-type tumor organoids
(left) and Lgr5–DTR–GFP mice-derived tumor organoids, with relatively high LGR5 expression (the percentage of LGR5 expression is greater than 1%)
(middle) or low LGR5 expression (the percentage of LGR5 expression is lesser than 1%) (right) during regular expansion to DT/sorafenib treatment. −/+:
drug treatment during the expansion period; +/+: drug treatment since the initial culture day (unpaired T test). d, e Representative FACS plots showing
that LGR5–GFP+ cells are depleted by DT treatment, for high LGR5 expression organoid strains (d) and low LGR5 expression organoid strains (e).
f Outlines of the experimental strategy used to assess the efficacy of DT/sorafenib/5-FU administration on allograft tumors in mice. g Representative
FACS plots from experiments validating the strategy to deplete LGR5+ cells. h A representative growth curve showing the volumes of tumors derived from
the vehicle control group and the DT-administered group (n= 8, two-way ANOVA). i The weight of tumors from vehicle control, DT, 5-FU, or sorafenib-
treated groups, on the day of mice sacrifice (control vs. sorafenib vs. 5-FU vs. DT: 0.34 ± 0.078 g, n= 18 vs. 0.18 ± 0.047 g, n= 15 vs. 0.19 ± 0.033 g, n= 15
vs. 0.15 ± 0.027 g, n= 19). Mean ± SEM. Source data are provided as a Source Data file.
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Fig. 7 Combination of LGR5 lineage ablation with sorafenib does not enhance the efficacy. a Outline of the experimental strategy to assess the
combinatory effect of LGR5 lineage ablation with sorafenib. Sorafenib and DT were administered every other day for in total 10 days since visualization of
tumor formation after organoid engraftment. b Representative growth curves showing tumor volumes in the vehicle control (CTR), sorafenib, DT, and
sorafenib+DT-treated groups. Black arrow: onset of administration. c Tumor masses from these four groups (CTR vs. sorafenib vs. DT. vs. sorafenib+ DT:
0.45 ± 0.09 g, n= 8 vs. 0.25 ± 0.06 g, n= 8 vs. 0.28 ± 0.043 g, n= 8 vs. 0.29 ± 0.09, n= 8). d Images showing tumors from these four groups. e Outlines
of the experimental strategy for assessing the effects of combining LGR5 lineage ablation and sorafenib treatment. Sorafenib, DT, or the combination were
administered immediately since transplantation of the organoids every other day, for in total 10 days. f Representative growth curves showing tumor
volumes of the four groups. Black arrow: onset of administration. g The tumor masses of these four groups (CTR vs. sorafenib vs. DT vs. sorafenib+DT:
0.21 ± 0.03 g, n= 8 vs. 0.16 ± 0.03 g, n= 8 vs. 0.09 ± 0.02 g, n= 8 vs. 0.12 ± 0.03 g, n= 8). h Images showing the tumors from the different groups. Mean
± SEM. Source data are provided as a Source Data file.
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Fig. 8 Combination of LGR5 lineage ablation with 5-FU results in enhanced anticancer efficacy. a Outline of the experimental strategy to assess the
combinatory effect of LGR5 lineage ablation with 5-FU. Following tumor organoid allografting, 5-FU was administered for the first half of the experiment
(every other day, for in total 6 days). DT was administered for the second half of the experiment (every other day, for in total 6 days). b Representative
growth curves showing tumor volumes in the vehicle control group (CTR), the 5-FU monotherapy group, the DT administration-only group, and the hybrid
5-FU/DT group. Black arrow: onset of DT administration. c Tumor masses from these four groups (control vs. 5-FU vs. DT vs. 5-FU-DT: 0.33 ± 0.076 g,
n= 12 vs. 0.25 ± 0.066 g, n= 8 vs. 0.29 ± 0.052 g, n= 8 vs. 0.13 ± 0.020 g, n= 8). d Representative images showing tumors from these four groups.
e Outlines of the experimental strategy for assessing the effects of combined LGR5 lineage ablation and 5-FU treatment. 5-FU, DT, or the combination were
administered since organoid engraftment every other day, for in total 12 days. f Representative growth curves showing tumor volumes of the four groups.
Black arrow: onset of administration (two-way ANOVA). g The tumor masses of these four groups (control vs. 5-FU vs. DT vs. 5-FU+DT: 0.24 ± 0.056,
n= 11 vs. 0.21 ± 0.048 g, n= 8 vs. 0.16 ± 0.027 g, n= 11 vs. 0.069 ± 0.007 g, n= 8). h Representative images showing the tumors from the different
groups. Mean ± SEM. Source data are provided as a Source Data file.
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Data availability
The RNA-seq data have been deposited in the GEO database under the accession code
GSE137517. The human LGR5 expression and HCC mutation data referenced during the
study are available in a public repository from the TCGA and LICA databases. The
source data underlying Figs. 1c-d, 2, 3e, 4d, f, h, i, p, 5b, f, h-i, 6c, h, I, 7b, c, f, g, 8b, c, f, g
and Supplementary Figs. 2a, g, 3, 4, 6b-c, 7b-e, 8a-b, 9, 10c-d, 11, 12a-b and 13g-h are
provided as a Source Data file. All the other data supporting the findings of this study are
available within the article and its supplementary information files and from the
corresponding author upon reasonable request. A reporting summary for this article is
available as a Supplementary Information file.
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